Underwriters have snapped up another 1 million shares of GlycoMimetics Inc. stock, the Gaithersburg biotech announced this week, marking the close of its $64.4 million initial public offering.
GLYC debuted on the Nasdaq last week in the Washington region’s first IPO of 2014, selling a total 8 million shares at $8 apiece. Net proceeds to the company will be around $57.4 million, much of which will pay expenses to advance one of its oncology drug candidates through the clinic.
{iframe}http://www.bizjournals.com/washington/blog/techflash/2014/01/glyomimetics-closes-ipo-underwriters.html?ana=e_du_pap&s=article_du&ed=2014-01-16{/iframe}